Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of an RSV+HMPV protein vaccine candidate in adults aged 60 years and older
NL-OMON61623Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of VXB-221 and VXB-213 in respiratory syncytial virus disease (RSV) and human metapneumovirus infection (HMPV), sponsored by Sanofi. Primary endpoints: Occurrence of the first episode of RSV-LRTD and Occurrence of the first episode of HMPV-LRTD. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
VXB-221VXB-213
03
Conditions
respiratory syncytial virus disease (RSV)human metapneumovirus infection (HMPV)
Beyond the preview
Go deeper on NL-OMON61623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61623.